Cannabis Global (OTC: CBGL), a cannabinoid and hemp-extract, science-forward company developing infusion and delivery technologies, has added tetrahydrocannabinol (“THC”) to its Project Varin research program. CBGL is conducting the program in partnership with Natural Plant Extract of California Inc (“NPE”), a licensed and regulated cannabis products manufacturer. The objective of the program is to demonstrate the cost advantages of using the company’s proprietary and provisional patent-pending nanoparticle and nanofiber technologies to change the cost model as it related to adding THC to various products. Cannabis Global filed six provisional patent applications last year, including one which outlined the methods and technologies to create new forms of polymeric cannabinoid nanoparticles. CBGl is also including other cannabinoids, such as tetrahydrocannabivarin (“THC-V”) and cannabinol (“CBN”) in its research. The company intends to add THC to the program with the end goal of creating new particles and fibers that product formulators and manufacturers can use. “Our goal with THC and Project Varin is simple: delivering to the cannabis industry a better form of THC that is substantially more effective, less expensive, and free of the potentially dangerous chemicals used in currently available formulations,” Cannabis Global CEO Arman Tabatabaei stated in the press release. “Over the past few months, our research program has made substantial progress toward these goals with strong successes in CBD, Tetrahydrocannabivarin (‘THC-V’), and Cannabinol (‘CBN’). By applying what we have learned thus far to THC, we hope to formulate an entirely new class of THC product for the cannabis industry that will be included under our nanotechnology provisional patent filing and future patent applications.”
To view the full press release, visit https://ibn.fm/BHcxZ
About Cannabis Global Inc.
Cannabis Global, formerly known as MCTC Holdings Inc., is a fully audited and reporting company with the U.S. Securities & Exchange Commission. The company is an emerging force in the area of cannabinoid sciences and highly bioavailable hemp- and cannabis-infusion technologies. The company does not engage in the production, distribution or sales of any controlled substances, including marijuana. CBGL has an actively growing portfolio of intellectual property, having filed six patents in the areas of cannabinoid delivery systems and cannabinoid polymeric nanoparticles. The company markets its consumer products under the Hemp You Can Feel brand name. Cannabis Global launched its Project Varin early in 2020, designed to develop new delivery methods for rare cannabinoid tetrahydrocannabivarin (“THV-C”) and to develop products based on this cannabinoid. For more information about the company, visit www.CannabisGlobalInc.com.
NOTE TO INVESTORS: The latest news and updates relating to CBGL are available in the company’s newsroom at http://ibn.fm/CBGL
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.